Efficacy comparison of immune treating strategies for NSCLC patients with negative PD-L1 expression

被引：3

作者：

Ding, Kaiyue ^{[1
,2
,3
,4
]}

Yi, Minhan ^{[1
,5
]}

Liang, Hui ^{[4
]}

Li, Zhongkui ^{[4
]}

Zhang, Yuan ^{[1
,2
,6
]}

机构：

[1] Cent South Univ, Xiangya Hosp, Dept Resp Med, Changsha, Hunan, Peoples R China

[2] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Hunan, Peoples R China

[3] Cent South Univ, Xiangya Hosp 2, Dept Nephrol, Hunan Key Lab Kidney Dis & Blood Purificat, Changsha, Hunan, Peoples R China

[4] Cent South Univ, Xiangya Sch Med, Changsha, Hunan, Peoples R China

[5] Cent South Univ, Sch Life Sci, Changsha, Hunan, Peoples R China

[6] Cent South Univ, Xiangya Hosp, Ctr Resp Med, Changsha, Hunan, Peoples R China

来源：

EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2022年 / 18卷 / 07期

基金：

芬兰科学院;

关键词：

Immune checkpoint inhibitors; negative PD-L1 expression; NSCLC; overall survival; Progression-free survival; CELL LUNG-CANCER; METASTATIC NONSQUAMOUS NSCLC; 1ST-LINE TREATMENT; OPEN-LABEL; PLUS CHEMOTHERAPY; PHASE-3; NIVOLUMAB; ATEZOLIZUMAB; CARBOPLATIN; DOCETAXEL;

D O I：

10.1080/1744666X.2022.2088510

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background We intended to compare and grade the proposed immune treating strategies for non-small cell lung cancer (NSCLC) with negative Programmed Cell Death Ligand 1(PD-L1). Methods We compared the efficacy of single immune checkpoint inhibitor (ICI), single ICI plus chemotherapy, and doublet ICIs with chemotherapy alone, as well as single ICI plus radiotherapy with single ICI for negative PD-L1 (<1%) NSCLC patients. Hazard Ratio (HR) and 95% confidence interval (CI) of progression-free survival (PFS) and overall survival (OS) were used as outcomes. Results We included 23 randomized control trials with 4665 patients. Compared with chemotherapy alone, single ICI, single ICI plus chemotherapy and doublet ICIs all showed a better OS (0.84 [0.71, 0.99] ; 0.77 [0.69, 0.85] ; 0.64 [0.53, 0.77])), while single ICI plus chemotherapy and doublet ICIs showed a better PFS (0.68 [0.61, 0.75] ; 0.69 [0.56, 0.85]). Additionally, single ICI plus radiotherapy obtained a greater pooled PFS (0.49 [0.28-0.87]) than single ICI. Conclusions Both single ICI plus chemotherapy and doublet ICIs were probably better treatment decisions than chemotherapy alone for negative PD-L1 NSCLC patients. Also, single ICI plus radiotherapy carved out a new strategy.

引用

页码：759 / 771

页数：13

共 64 条

[41] Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial [J].

Rizvi, Naiyer A. ;

Cho, Byoung Chul ;

Reinmuth, Niels ;

Lee, Ki Hyeong ;

Luft, Alexander ;

Ahn, Myung-Ju ;

van den Heuvel, Michel M. ;

Cobo, Manuel ;

Vicente, David ;

Smolin, Alexey ;

Moiseyenko, Vladimir ;

Antonia, Scott J. ;

Le Moulec, Sylvestre ;

Robinet, Gilles ;

Natale, Ronald ;

Schneider, Jeffrey ;

Shepherd, Frances A. ;

Geater, Sarayut Lucien ;

Garon, Edward B. ;

Kim, Edward S. ;

Goldberg, Sarah B. ;

Nakagawa, Kazuhiko ;

Raja, Rajiv ;

Higgs, Brandon W. ;

Boothman, Anne-Marie ;

Zhao, Luping ;

Scheuring, Urban ;

Stockman, Paul K. ;

Chand, Vikram K. ;

Peters, Solange .

JAMA ONCOLOGY, 2020, 6 (05) :661-674

[42] Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab [J].

Saenger, Yvonne ;

Magidson, Jay ;

Liaw, Bobby ;

de Moll, Ellen ;

Harcharik, Sara ;

Fu, Yichun ;

Wassmann, Karl ;

Fisher, David ;

Kirkwood, John ;

Oh, William K. ;

Friedlander, Philip .

CLINICAL CANCER RESEARCH, 2014, 20 (12) :3310-3318

[43] Tumor mutational load predicts survival after immunotherapy across multiple cancer types [J].

Samstein, Robert M. ;

Lee, Chung-Han ;

Shoushtari, Alexander N. ;

Hellmann, Matthew D. ;

Shen, Ronglai ;

Janjigian, Yelena Y. ;

Barron, David A. ;

Zehir, Ahmet ;

Jordan, Emmet J. ;

Omuro, Antonio ;

Kaley, Thomas J. ;

Kendall, Sviatoslav M. ;

Motzer, Robert J. ;

Hakimi, A. Ari ;

Voss, Martin H. ;

Russo, Paul ;

Rosenberg, Jonathan ;

Iyer, Gopa ;

Bochner, Bernard H. ;

Bajorin, Dean F. ;

Al-Ahmadie, Hikmat A. ;

Chaft, Jamie E. ;

Rudin, Charles M. ;

Riely, Gregory J. ;

Baxi, Shrujal ;

Ho, Alan L. ;

Wong, Richard J. ;

Pfister, David G. ;

Wolchok, Jedd D. ;

Barker, Christopher A. ;

Gutin, Philip H. ;

Brennan, Cameron W. ;

Tabar, Viviane ;

Mellinghoff, Ingo K. ;

DeAngelis, Lisa M. ;

Ariyan, Charlotte E. ;

Lee, Nancy ;

Tap, William D. ;

Gounder, Mrinal M. ;

D'Angelo, Sandra P. ;

Saltz, Leonard ;

Stadler, Zsofia K. ;

Scher, Howard I. ;

Baselga, Jose ;

Razavi, Pedram ;

Klebanoff, Christopher A. ;

Yaeger, Rona ;

Segal, Neil H. ;

Ku, Geoffrey Y. ;

DeMatteo, Ronald P. .

NATURE GENETICS, 2019, 51 (02) :202-+

[44] Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel [J].

Schuette, W ;

Nagel, S ;

Blankenburg, T ;

Lautenschlaeger, C ;

Hans, K ;

Schmidt, EW ;

Dittrich, I ;

Schweisfurth, H ;

von Weikersthal, LF ;

Raghavachar, A ;

Reissig, A ;

Serke, M .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (33) :8389-8395

[45]

SEER Cancer Statistics Review, 2018, CANC STAT FACTS LUNG

[46] First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer [J].

Shaw, Alice T. ;

Bauer, Todd M. ;

de Marinis, Filippo ;

Felip, Enriqueta ;

Goto, Yasushi ;

Liu, Geoffrey ;

Mazieres, Julien ;

Kim, Dong-Wan ;

Mok, Tony ;

Polli, Anna ;

Thurm, Holger ;

Calella, Anna M. ;

Peltz, Gerson ;

Solomon, Benjamin J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (21) :2018-2029

[47] Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer [J].

Shi, Yunfei ;

Lei, Youming ;

Liu, Li ;

Zhang, Shiyue ;

Wang, Wenjing ;

Zhao, Juan ;

Zhao, Songhui ;

Dong, Xiaowei ;

Yao, Ming ;

Wang, Kai ;

Zhou, Qing .

CANCER MEDICINE, 2021, 10 (07) :2216-2231

[48] Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer [J].

Shin, Junghoon ;

Chung, Jin-Haeng ;

Kim, Se Hyun ;

Lee, Kyu Sang ;

Suh, Koung Jin ;

Lee, Ji Yun ;

Kim, Ji-Won ;

Lee, Jeong-Ok ;

Kim, Jin-Won ;

Kim, Yu-Jung ;

Lee, Keun-Wook ;

Kim, Jee Hyun ;

Bang, Soo-Mee ;

Lee, Jong-Seok .

CANCER RESEARCH AND TREATMENT, 2019, 51 (03) :1086-1097

[49] Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC [J].

Socinski, M. A. ;

Jotte, R. M. ;

Cappuzzo, F. ;

Orlandi, F. ;

Stroyakovskiy, D. ;

Nogami, N. ;

Rodriguez-Abreu, D. ;

Moro-Sibilot, D. ;

Thomas, C. A. ;

Barlesi, F. ;

Finley, G. ;

Kelsch, C. ;

Lee, A. ;

Coleman, S. ;

Deng, Y. ;

Shen, Y. ;

Kowanetz, M. ;

Lopez-Chavez, A. ;

Sandler, A. ;

Reck, M. ;

Ahualli, A. ;

Jarchum, G. ;

Kaen, D. L. ;

Kahl, S. ;

Kotliar, M. ;

Kowalyszyn, R. D. ;

Lerzo, G. ;

Magri, I ;

Martin, C. ;

Pastor, A. ;

Picon, P. ;

Streich, G. ;

Varela, M. ;

Blinman, P. ;

Boyer, M. ;

Crombie, C. ;

Gauden, S. ;

Gill, S. ;

Hughes, B. ;

John, T. ;

Joshi, A. ;

Kosmider, S. ;

Lewis, C. ;

Millward, M. ;

Nordman, I ;

Nott, L. ;

O'Byrne, K. ;

Parnis, F. ;

Potasz, N. ;

Richardson, G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (24) :2288-2301

[50] IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC [J].

Socinski, Mark A. ;

Nishio, Makoto ;

Jotte, Robert M. ;

Cappuzzo, Federico ;

Orlandi, Francisco ;

Stroyakovskiy, Daniil ;

Nogami, Naoyuki ;

Rodriguez-Abreu, Delvys ;

Moro-Sibilot, Denis ;

Thomas, Christian A. ;

Barlesi, Fabrice ;

Finley, Gene ;

Kong, Shengchun ;

Lee, Anthony ;

Coleman, Shelley ;

Zou, Wei ;

McCleland, Mark ;

Shankar, Geetha ;

Reck, Martin .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) :1909-1924

← 1 2 3 4 5 6 7 →